NEWS
Future PharmaTech Signs ED Drug Licensing Deal with PBF Group
The licensing agreement grants PBF exclusive rights in Taiwan and priority negotiation rights in Greater China for an innovative ED therapy derived from three approved drugs. Developed via the 505(b)(2) pathway, the platform enables faster market entry with lower clinical risk.
Future PharmaTech’s Two Lead Drug Candidates Set to Enter Phase II Trials
Focusing on vascular dementia and ED treatment, two promising compounds are set to enter Phase II clinical trials with strong global market potential.
Prof. Chao Ming-Wei Leads R&D Strategy – Dementia Drug Poised for Clinical Entry
Prof. Chao, an expert in toxicology, is advising Future PharmaTech’s innovative drug program. The team is preparing to begin clinical trials targeting vascular dementia.
